A new Science Translational Medicine paper is first to report how editing a portion of stem cells with CRISPR/Cas9 is sufficient for long-term reactivation of therapeutic hemoglobin
A proof-of-principle study published in Nature Materials shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells. (Photos, diagram available for media use.)
Dr. David MacPherson discusses the state of small cell lung cancer research, how his lab is tackling this deadly disease, and what makes him excited for the future